Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: billkirn who wrote (3417)	12/26/1997 4:55:00 AM
From: billkirn	Respond to of 6136

TO ALL: I received this email today. Anyone know anything about this issue with GART. >> Bill, I am an Oncology Sales Rep for Schering-Plough Pharm. I recently talked to a group of Cancer researchers dealing with many Phase 1 drugs. I was told that Lilly recently pulled their GART inhibitor off trials due to some very serious side effects. I am very pro AGPH as it is my largest holding and I continue to buy more as money permits. Just thought that you may like to know this. Maybe this was one of the factors which influenced Roche. I wonder if others on the stockletter may know anything. I do not subscribe, so I was wondering if you could pass this message along. Thanks Keith<<